How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

15,635 results for

Squamous Cell Carcinoma of the Skin

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

13881. S0216, Combination Chemotherapy and RT in Treating Patients With Stage III or Stage IV Head and Neck Cancer

adequately treated basal cell or squamous cell skin cancer, carcinoma in situ of the cervix, or adequately treated stage I or II cancer currently in complete remission No evidence of pre-existing peripheral neuropathy No active systemic infection No history of hypersensitivity reaction to products containing polysorbate 80 PRIOR CONCURRENT THERAPY: Biologic therapy Not specified Chemotherapy No prior chemotherapy Endocrine therapy Not specified Radiotherapy See Disease Characteristics No prior (...) trial to study the effectiveness of combination chemotherapy and radiation therapy in treating patients with stage III or stage IV head and neck cancer. Condition or disease Intervention/treatment Phase Head and Neck Cancer Drug: cisplatin Drug: docetaxel Drug: fluorouracil Radiation: radiation therapy Phase 2 Detailed Description: OBJECTIVES: Determine the overall survival of patients with stage III or IV squamous cell head and neck cancer treated with docetaxel, cisplatin, and fluorouracil

2003 Clinical Trials

13882. Suramin and Paclitaxel in Treating Women With Stage IIIB-IV Breast Cancer

to compounds of similar chemical or biological composition to Cremophor No concurrent uncontrolled illness that would preclude study compliance No ongoing or active infection No uncontrolled diabetes mellitus No psychiatric illness or social situations that would preclude study compliance No other malignancy within the past 5 years except basal cell or squamous cell skin cancer or carcinoma in situ of the cervix See Disease Characteristics At least 3 weeks since prior chemotherapy (6 weeks for nitrosoureas (...) ) Information provided by (Responsible Party): National Cancer Institute (NCI) Study Details Study Description Go to Brief Summary: This phase I/II trial studies the best dose of suramin when given together with paclitaxel in treating women with stage IIIB-IV breast cancer. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Suramin may increase the effectiveness of paclitaxel by making tumor cells more sensitive to the drug. Condition or disease

2003 Clinical Trials

13883. 3-AP in Treating Patients With Advanced Prostate Cancer

cell skin cancer or any stage I malignancy curatively resected more than 5 years ago No active uncontrolled infectious process No other life-threatening illness No peripheral neuropathy greater than grade 2 PRIOR CONCURRENT THERAPY: Biologic therapy At least 2 weeks since prior biologic therapy Chemotherapy At least 3 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin) and recovered No more than 1 prior chemotherapy regimen for metastatic disease Endocrine therapy See Disease (...) Summary: RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of 3-AP in treating patients who have advanced prostate cancer that has been previously treated with hormone therapy. Condition or disease Intervention/treatment Phase Prostate Cancer Drug: triapine Phase 2 Detailed Description: OBJECTIVES: Determine the response rate in patients with advanced hormone-refractory prostate

2003 Clinical Trials

13884. Isotretinoin, Interferon Alfa, and Vitamin E in Treating Patients With Stage III or Stage IV Head and Neck Cancer

or disease Intervention/treatment Phase Head and Neck Cancer Biological: recombinant interferon alfa Dietary Supplement: vitamin E Drug: isotretinoin Procedure: adjuvant therapy Phase 3 Detailed Description: OBJECTIVES: Determine the efficacy of adjuvant isotretinoin, interferon alfa, and vitamin E, in terms of incidence of primary disease recurrence and secondary primary tumor development, in patients with stage III or IV squamous cell carcinoma of the head and neck previously treated with definitive (...) phosphatase no greater than 2 times ULN Renal Creatinine no greater than 1.2 mg/dL Other Not pregnant or nursing Negative pregnancy test Fertile patients must use effective contraception for 1 month prior to, during, and for 1 month after study therapy Electrolytes normal Fasting serum triglyceride level no greater than 2 times ULN (anti-triglyceride medication allowed) No other malignancy within the past 2 years except localized basal cell or squamous cell skin cancer No other concurrent medical

2003 Clinical Trials

13885. Radiation Therapy and Chemotherapy in Treating Patients With Locally Advanced Cervical Cancer

-energy x-rays to damage tumor cells. Drugs used in chemotherapy, such as topotecan and cisplatin, use different ways to stop tumor cells from dividing so they stop growing or die. Combining radiation therapy with chemotherapy may kill more tumor cells. Condition or disease Intervention/treatment Phase Cervical Adenocarcinoma Cervical Squamous Cell Carcinoma Stage IB Cervical Cancer Stage IIA Cervical Cancer Stage IIB Cervical Cancer Stage III Cervical Cancer Stage IVA Cervical Cancer Drug: Topotecan (...) : CTRP (Clinical Trial Reporting Program) ) CDR0000270680 GOG-9913 GOG-9913 ( Other Identifier: Gynecologic Oncology Group ) GOG-9913 ( Other Identifier: CTEP ) First Posted: February 6, 2003 Last Update Posted: December 31, 2014 Last Verified: December 2014 Additional relevant MeSH terms: Layout table for MeSH terms Carcinoma Carcinoma, Squamous Cell Adenocarcinoma Uterine Cervical Neoplasms Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type Neoplasms Neoplasms, Squamous Cell Uterine

2003 Clinical Trials

13886. S0200 Carboplatin With or Without Doxil in Patients With Recurrent Ovarian Cancer

Bilirubin no greater than ULN Renal Creatinine no greater than 1.9 mg/dL Cardiovascular No New York Heart Association class II-IV cardiac disease No clinical evidence of congestive heart failure Ejection fraction greater than 50% by MUGA or 2-dimensional echocardiogram Other Not pregnant or nursing Fertile patients must use effective contraception No other malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer, carcinoma in situ of the cervix, or incidental (...) Group: peritoneal cavity cancer recurrent ovarian epithelial cancer stage III ovarian epithelial cancer stage IV ovarian epithelial cancer Additional relevant MeSH terms: Layout table for MeSH terms Ovarian Neoplasms Carcinoma, Ovarian Epithelial Peritoneal Neoplasms Endocrine Gland Neoplasms Neoplasms by Site Neoplasms Ovarian Diseases Adnexal Diseases Genital Diseases, Female Genital Neoplasms, Female Urogenital Neoplasms Endocrine System Diseases Gonadal Disorders Carcinoma Neoplasms, Glandular

2002 Clinical Trials

13887. Diagnostic Trial in Patients Who Are Undergoing Surgery for Early Stage Mouth Cancer

consent prior to registration or any study-related procedures. Female patient of childbearing potential must have negative serum pregnancy test within 30 daysprior to registration. If the patient is a survivor of a prior cancer, ALL of the following criteria are met: Patient has undergone potentially curative therapy for all prior malignancies, No evidence of any prior malignancies for at least 5 years with no evidence of recurrence (except for effectively treated basal cell or squamous carcinoma (...) the negativity of the other cervical lymph nodes in patients with stage I or II squamous cell carcinoma of the oral cavity. Determine the extent and pattern of disease spread in the nodal bed in these patients. Obtain data on the use of immunohistochemistry to assess nodes in these patients. Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Actual Enrollment : 161 participants Intervention Model: Single Group Assignment Masking: None (Open Label) Primary

2002 Clinical Trials

13888. Study of T900607-Sodium in Previously Treated Patients With Ovarian Cancer.

cardiac disease, left ventricular ejection fraction (LVEF) of <50%, or acute anginal symptoms Patients who have received any investigational agent within 4 weeks of enrollment Patients who are pregnant or breast-feeding History of prior malignancy other than ovarian cancer within the last 5 years, except for adequately treated basal cell or squamous cell skin cancer or carcinoma in situ of the cervix History of central nervous system metastases or carcinomatous meningitis Major surgery within 4 weeks (...) Sponsor: Tularik Information provided by: Tularik Study Details Study Description Go to Brief Summary: The purpose of this study is to determine whether T900607-sodium is effective and safe in treating ovarian cancer. Condition or disease Intervention/treatment Phase Ovarian Neoplasms Drug: intravenous T900607-sodium Phase 2 Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Enrollment : 35 participants Allocation: Non-Randomized Intervention Model

2002 Clinical Trials

13889. SU5416 in Treating Patients With Persistent or Recurrent Cervical Cancer

the contacts provided below. For general information, Layout table for eligibility information Ages Eligible for Study: Child, Adult, Older Adult Sexes Eligible for Study: Female Accepts Healthy Volunteers: No Criteria DISEASE CHARACTERISTICS: Histologically confirmed cervical squamous cell carcinoma Persistent or recurrent disease with documented progression No nonsquamous cell cervical malignancies, including adenosquamous carcinoma At least 1 measurable lesion At least 20 mm by conventional techniques (...) in the absence of disease progression or unacceptable toxicity. Patients are followed every 3 months for 2 years, every 6 months for 3 years, and then annually thereafter. PROJECTED ACCRUAL: Approximately 19-51 patients will be accrued for this study within 8-23 months. Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Primary Purpose: Treatment Official Title: A Phase II Evaluation of SU5416 (NSC 696819) in Persistent or Recurrent Squamous Cell Carcinoma

2001 Clinical Trials

13890. Hepatic Arterial Infusion Plus Chemotherapy in Treating Patients With Colorectal Cancer Metastatic to the Liver

than ULN Creatinine clearance greater than 60 mL/min Not pregnant or nursing Negative pregnancy test Fertile patients must use effective contraception Adequate oral nutrition (at least 1,500 calories/day) Able to withstand major operative procedure No dehydration No severe anorexia No frequent nausea or vomiting No prior or concurrent malignancy within the past 5 years except basal cell or squamous cell skin cancer or carcinoma in situ of any organ No prior or concurrent malignancy associated (...) or die. Giving the drugs in different combinations and different ways may kill more tumor cells. Condition or disease Intervention/treatment Phase Adenocarcinoma of the Colon Adenocarcinoma of the Rectum Liver Metastases Recurrent Colon Cancer Recurrent Rectal Cancer Stage IV Colon Cancer Stage IV Rectal Cancer Drug: floxuridine Drug: dexamethasone Drug: oxaliplatin Drug: capecitabine Phase 2 Detailed Description: OBJECTIVES: I. Determine the safety and toxicity of hepatic arterial infusion

2001 Clinical Trials

13891. Combination Chemotherapy and Radiation Therapy in Treating Patients With Pancreatic Cancer

uncontrolled serious medical or psychiatric illness that would preclude study compliance No other malignancy within the past 5 years except limited or curatively treated basal cell or squamous cell skin cancer or carcinoma in situ of the cervix Not pregnant or nursing Negative pregnancy test Fertile patients must use effective contraception PRIOR CONCURRENT THERAPY: Biologic therapy: See Disease Characteristics Chemotherapy: See Disease Characteristics Endocrine therapy: See Disease Characteristics (...) for Clinical Trials in Oncology Collaborator: National Cancer Institute (NCI) Information provided by (Responsible Party): Alliance for Clinical Trials in Oncology Study Details Study Description Go to Brief Summary: RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining chemotherapy with radiation therapy may kill more tumor cells. PURPOSE: Phase II trial to study

2001 Clinical Trials

13892. Liposomal Doxorubicin and Gemcitabine in Treating Women With Metastatic Breast Cancer

Cardiovascular: No prior cardiac disease within the past 5 years OR LVEF at least 50% Other: No prior uncontrolled seizures No uncontrolled systemic infection No anthracycline resistance No other malignancy within the past 5 years except curatively treated basal cell or squamous cell skin cancer or carcinoma in situ of the cervix Not pregnant or nursing Negative pregnancy test Fertile patients must use effective contraception PRIOR CONCURRENT THERAPY: Biologic therapy: No prior trastuzumab (Herceptin (...) : January 27, 2003 Last Update Posted : December 18, 2013 Sponsor: Pharmatech Oncology Information provided by: National Cancer Institute (NCI) Study Details Study Description Go to Brief Summary: RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of combining liposomal doxorubicin with gemcitabine in treating women who have metastatic breast cancer. Condition or disease Intervention

2001 Clinical Trials

13893. Curcumin for the Prevention of Colon Cancer

) Alkaline phosphatase less than 1.5 times ULN Bilirubin less than 1.5 mg/dL Renal: Creatinine less than 1.7 mg/dL Other: Not pregnant or nursing Negative pregnancy test Fertile patients must use effective contraception No prior cancer except surgically resected basal cell or squamous cell skin cancer No history of peptic ulcer disease, gastrointestinal bleeding from gastric or duodenal ulcers, or gastrin secreting tumors No history of unreliability or noncompliance (missing pretreatment appointment more (...) Update Posted: December 21, 2012 Last Verified: December 2012 Keywords provided by University of Michigan Rogel Cancer Center: colon cancer Additional relevant MeSH terms: Layout table for MeSH terms Colorectal Neoplasms Intestinal Neoplasms Gastrointestinal Neoplasms Digestive System Neoplasms Neoplasms by Site Neoplasms Digestive System Diseases Gastrointestinal Diseases Colonic Diseases Intestinal Diseases Rectal Diseases Curcumin Anti-Inflammatory Agents, Non-Steroidal Analgesics, Non-Narcotic

2001 Clinical Trials

13894. Biological Therapy in Treating Women With Stage IV Breast Cancer

No other prior or concurrent malignancy within the past 5 years except curatively treated squamous cell carcinoma in situ of the cervix, basal cell skin cancer, or any other curatively treated disease in complete remission PRIOR CONCURRENT THERAPY: Biologic therapy: See Disease Characteristics Prior trastuzumab allowed for phase I Chemotherapy: See Disease Characteristics At least 4 weeks since prior chemotherapy Endocrine therapy: See Disease Characteristics Concurrent hormonal therapy for breast (...) Investigation Committee ) WSU-0312004412 ( Other Identifier: Wayne State University - Human Investigation Committee ) First Posted: January 27, 2003 Last Update Posted: February 17, 2016 Last Verified: February 2016 Keywords provided by Lawrence Lum, Barbara Ann Karmanos Cancer Institute: stage IV breast cancer recurrent breast cancer ductal breast carcinoma Additional relevant MeSH terms: Layout table for MeSH terms Breast Neoplasms Neoplasms by Site Neoplasms Breast Diseases Skin Diseases Sargramostim

2001 Clinical Trials

13895. MEN-10755 in Treating Patients With Progressive Prostate Cancer That Has Not Responded to Hormone Therapy

disease No myocardial infarction within the past 6 months No cardiac insufficiency Normal cardiac function by MUGA scan and 12-lead EKG Other: No other prior or concurrent malignancy except basal cell or squamous cell skin cancer No uncontrolled systemic nonmalignant disease or infection No psychological, familial, or geographical conditions that would preclude compliance PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: At least 4 weeks since prior chemotherapy Endocrine therapy (...) : July 24, 2012 Sponsor: European Organisation for Research and Treatment of Cancer - EORTC Information provided by (Responsible Party): European Organisation for Research and Treatment of Cancer - EORTC Study Details Study Description Go to Brief Summary: RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of MEN-10755 in treating patients who have progressive prostate cancer

2001 Clinical Trials

13896. ZD 1839 Plus Combination Chemotherapy in Treating Patients With Locally Advanced, Locally Recurrent, or Metastatic Colorectal Cancer

symptoms as indicated by more than 3 loose stools daily in patients without a colostomy or ileostomy No other malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer or adequately treated noninvasive carcinomas No other concurrent medical or psychiatric condition that would preclude study Not pregnant or nursing Negative pregnancy test Fertile patients must use effective contraception PRIOR CONCURRENT THERAPY: Biologic therapy: At least 12 months since prior (...) may interfere with the growth of tumor cells and slow the growth of the tumor. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining ZD 1839 with combination chemotherapy may kill more tumor cells. Condition or disease Intervention/treatment Phase Colorectal Cancer Drug: fluorouracil Drug: gefitinib Drug: irinotecan hydrochloride Drug: leucovorin calcium Phase 1 Detailed Description: OBJECTIVES: I. Determine the maximum tolerated

2001 Clinical Trials

13897. Gemcitabine With or Without Erlotinib in Treating Patients With Unresectable Locally Advanced or Metastatic Pancreatic Cancer

active infection No other serious underlying medical, psychological, or geographical condition that would preclude study participation No prior allergic reaction to compounds with similar chemical or biologic composition to erlotinib No other prior malignancy within the past 5 years except cancer in situ or basal cell or squamous cell skin cancer PRIOR CONCURRENT THERAPY: Biologic therapy: No concurrent biologic therapy or immunotherapy Chemotherapy: No prior chemotherapy except fluorouracil (...) from growing. Combining chemotherapy and biological therapy may kill more tumor cells. It is not yet known if gemcitabine is more effective with or without erlotinib in treating pancreatic cancer. PURPOSE: Randomized phase III trial to determine the effectiveness of gemcitabine with and without erlotinib in treating patients who have unresectable locally advanced or metastatic pancreatic cancer. Condition or disease Intervention/treatment Phase Pancreatic Cancer Drug: erlotinib hydrochloride Drug

2001 Clinical Trials

13898. S0310: Vaccine Therapy in Treating Patients With Stage IIIB or Stage IV Bronchoalveolar Lung Cancer

and older (Adult, Older Adult) Sexes Eligible for Study: All Accepts Healthy Volunteers: No Criteria DISEASE CHARACTERISTICS: Diagnosis* of 1 of the following by radiological features and clinical presentation: Bronchoalveolar carcinoma (BAC) Diffuse or ground glass appearance Adenocarcinoma with bronchoalveolar features BAC with focal invasion NOTE: *Histological confirmation (excluding fine needle aspiration or bronchial brushings or washings) is required after the tumor tissue has been procured (...) albumin Dimethyl sulfoxide Porcine trypsin Fetal bovine serum Recombinant benzonase Other components of the vaccine or CG6444 adenoviral vector used in this study Other Not pregnant or nursing Negative pregnancy test Fertile patients must use effective contraception No poor nutritional status No psychiatric illness or social situation that would preclude study compliance or increase operative risk No other malignancy within the past 5 years except adequately treated basal cell or squamous cell skin

2003 Clinical Trials

13899. Bortezomib With or Without Irinotecan in Treating Patients With Cancer of the Gastroesophageal Junction or Stomach

receiving combination anti-retroviral therapy are excluded from the study Patients with a concurrent malignancy are excluded (except for early stage squamous cell carcinoma of the skin or cervix which can be treated locally); patients with an advanced malignancy within the past five years are not eligible; patients with a prior malignancy who have been disease free for five years are eligible Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study (...) the enzymes necessary for tumor cell growth. Drugs used in chemotherapy such as irinotecan use different ways to stop tumor cells from dividing so they stop growing or die. Combining bortezomib with irinotecan may kill more tumor cells. Condition or disease Intervention/treatment Phase Adenocarcinoma of the Gastroesophageal Junction Diffuse Adenocarcinoma of the Stomach Intestinal Adenocarcinoma of the Stomach Mixed Adenocarcinoma of the Stomach Recurrent Gastric Cancer Stage IIIB Gastric Cancer Stage

2003 Clinical Trials

13900. Second-line Intravenous Treatment For Recurrent Platinum-Sensitive Ovarian, Fallopian, Or Peritoneal Cancer

or previous malignancies with the exception of adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, incidental carcinoid, or other cancer from which the patient has been disease free for 5 years. Active uncontrolled infection requiring antibiotics. Concurrent severe medical problems unrelated to the malignancy which would limit full compliance with the study. Received radiation to more than 10% of bone. Prior treatment with topotecan or gemcitabine. Hypersensitivity (...) term outcome and side effects of this combination treatment. Since topotecan and gemcitabine have different mechanisms of action, the combination of these 2 drugs may provide better results than either drug alone. Prior studies suggest that the combination of topotecan and gemcitabine improves the effects on the tumor and also appeared to be well tolerated. Condition or disease Intervention/treatment Phase Peritoneal Cancer Ovarian Cancer Neoplasms, Ovarian Fallopian Tube Cancer Drug: Topotecan

2003 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>